Intrepida Bio, Inc., a San Diego, CA-based company that develop novel medicines that exploit the innate immune system to fight disease, raised an initial $9.5m in equity funding.
Backers included Sofinnova Investments and Canaan and original investors Indaco Venture Partners and Vertis SGR.
The company intends to use the funds for the investigational new drug (IND) application-enabling studies of its lead oncology program.
Co-founded by Joel F. Martin, Ph.D., president and chief executive officer, and Olivier Laurent, Ph.D., chief scientific officer, together with Biouniversa s.r.l., Intrepida Bio is a company dedicated to the discovery and development of medicines that modulate the innate immune system to fight cancer and other diseases.
The company designs proprietary monoclonal antibodies that block the novel targets BAG3 and its receptor IFITM-2 to thwart their ability to create a favorable environment for tumor growth.
The company’s Board of Directors includes:
– Dr. Martin,
– Mike Powell, Ph.D., general partner at Sofinnova Investments and chairman,
– David Kabakoff, Ph.D., executive partner of Sofinnova,
– Nina Kjellson, general partner at Canaan,
– Ellen Lubman, chief business officer at Impel NeuroPharma,
– Elizabeth Robinson, Ph.D., co-founder and vice chairman of Indaco Venture Partners SGR,
– Giovanni Rizzo, Ph.D., chief executive officer of Biouniversa.